CureVac announced the completion of a capital increase, which put serious pressure on the share price this week. Shares of the Tübingen-based biotech company were still trading at $10.58 on the NASDAQ before the announcement, but the stock fell significantly during the week. A new all-time low for this low was made yesterday at $8.7 . It started at $8.90 over the weekend. We warned early on sell signals for CureVac shares as a result of the capital increase. Meanwhile, the South Germans stopped placing stocks. Shares of CureVac (WKN: A2P71U, ISIN: NL0015 36031, Chart ), which has a total volume of approximately $250 million, were placed at an investment price of $9.25. „This is before CureVac’s subscription benefits and commissions and expenses are deducted,” the biotech company says of the proceeds from the issue, which will eventually end up in the company’s coffers. According to Goldman Sachs and Co. LLC, Jefferies LLC and SVB Securities LLC are the lead managers of the offering, while Van Lanschot Kempen (USA) Inc. served as chief manager of the proposal.